468 related articles for article (PubMed ID: 18289173)
1. Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats.
Lin CH; Huang JY; Ching CH; Chuang JI
J Pineal Res; 2008 Mar; 44(2):205-13. PubMed ID: 18289173
[TBL] [Abstract][Full Text] [Related]
2. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
[TBL] [Abstract][Full Text] [Related]
3. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Tapias V; Cannon JR; Greenamyre JT
J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
5. Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
Joyce JN; Der TC; Renish L; Osredkar T; Hagner D; Reploge M; Sakakibara S; Ueda S
Exp Neurol; 2004 May; 187(1):178-89. PubMed ID: 15081599
[TBL] [Abstract][Full Text] [Related]
6. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX
Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351
[TBL] [Abstract][Full Text] [Related]
7. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone.
Inden M; Kitamura Y; Takeuchi H; Yanagida T; Takata K; Kobayashi Y; Taniguchi T; Yoshimoto K; Kaneko M; Okuma Y; Taira T; Ariga H; Shimohama S
J Neurochem; 2007 Jun; 101(6):1491-1504. PubMed ID: 17459145
[TBL] [Abstract][Full Text] [Related]
8. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
Takeuchi H; Yanagida T; Inden M; Takata K; Kitamura Y; Yamakawa K; Sawada H; Izumi Y; Yamamoto N; Kihara T; Uemura K; Inoue H; Taniguchi T; Akaike A; Takahashi R; Shimohama S
J Neurosci Res; 2009 Feb; 87(2):576-85. PubMed ID: 18803299
[TBL] [Abstract][Full Text] [Related]
9. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
Testa CM; Sherer TB; Greenamyre JT
Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
[TBL] [Abstract][Full Text] [Related]
10. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
Sindhu KM; Saravanan KS; Mohanakumar KP
Brain Res; 2005 Jul; 1051(1-2):25-34. PubMed ID: 15992782
[TBL] [Abstract][Full Text] [Related]
11. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
Singh S; Singh K; Gupta SP; Patel DK; Singh VK; Singh RK; Singh MP
Brain Res; 2009 Aug; 1283():115-26. PubMed ID: 19520064
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
[TBL] [Abstract][Full Text] [Related]
13. Increased sensitivity of striatal dopamine release to H2O2 upon chronic rotenone treatment.
Milusheva E; Baranyi M; Kittel A; Sperlágh B; Vizi ES
Free Radic Biol Med; 2005 Jul; 39(1):133-42. PubMed ID: 15925285
[TBL] [Abstract][Full Text] [Related]
14. Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition.
McArthur S; Murray HE; Dhankot A; Dexter DT; Gillies GE
J Neurochem; 2007 Feb; 100(3):678-92. PubMed ID: 17116232
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA.
Granado N; Ares-Santos S; Oliva I; O'Shea E; Martin ED; Colado MI; Moratalla R
Neurobiol Dis; 2011 Jun; 42(3):391-403. PubMed ID: 21303698
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the time courses of selective gene expression and dopaminergic depletion induced by MPP+ in MN9D cells.
Wang J; Duhart HM; Xu Z; Patterson TA; Newport GD; Ali SF
Neurochem Int; 2008 May; 52(6):1037-43. PubMed ID: 18069091
[TBL] [Abstract][Full Text] [Related]
17. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
Saravanan KS; Sindhu KM; Mohanakumar KP
Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
[TBL] [Abstract][Full Text] [Related]
18. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
Norazit A; Meedeniya AC; Nguyen MN; Mackay-Sim A
Brain Res; 2010 Nov; 1360():119-29. PubMed ID: 20807515
[TBL] [Abstract][Full Text] [Related]
19. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.
Pellegrino D; Cicchetti F; Wang X; Zhu A; Yu M; Saint-Pierre M; Brownell AL
J Nucl Med; 2007 Jul; 48(7):1147-53. PubMed ID: 17574972
[TBL] [Abstract][Full Text] [Related]
20. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
